nyuuzyou/wikis huggingface dataset:
Darinaparsin (Darvias)

==Mechanism of action==
From the NCI Drug Dictionary: A small-molecule organic arsenical with potential antineoplastic activity. Although the exact mechanism of action is unclear, darinaparsin, a highly toxic metabolic intermediate of inorganic arsenicals (iAs) that occurs in vivo, appears to generate volatile cytotoxic arsenic compounds when glutathione (GSH) concentrations are low. The arsenic compounds generated from darinaparsin disrupt mitochondrial bioenergetics, producing reactive oxygen species (ROS) and inducing ROS-mediated tumor cell apoptosis; in addition, this agent or its byproducts may initiate cell death by interrupting the G2/M phase of the cell cycle and may exhibit antiangiogenic effects. Compared to inorganic arsenic compounds such as arsenic trioxide (As2O3), darinaparsin appears to exhibit a wide therapeutic window.
==Diseases for which it is used==
*Peripheral T-cell lymphoma
==History of changes in PMDA indication==
*2022-06-20: A drug with a new active ingredient indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma. (Based on SP-02)
==Also known as==
*Code names: SP-02L, ZIO-101
*Brand name: Darvias
Category:Drugs
Category:Intravenous medications
Category:Organoarsenicals
Category:PMDA approved in 2022
Darolutamide (Nubeqa)

==General information==
Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor, non-steroidal antiandrogen (NSAA) that competitively inhibits androgens by binding to androgen receptors and exhibiting antitumor activity by blocking testosterone-induced nuclear translocation of androgen receptors.Darolutamide (Nubeqa) package insert Darolutamide (Nubeqa) package insert (locally hosted backup)Nubeqa manufacturer's websiteMoilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykänen PS, Törmäkangas OP, Palvimo JJ, Kallio PJ. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015 Jul 3;5:12007. link to original article EuroPMC
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape or the prescribing information.
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Darolutamide (Nubeqa) package insert
*Darolutamide (Nubeqa) patient drug information (Chemocare)Darolutamide (Nubeqa) patient drug information (Chemocare)
*Darolutamide (Nubeqa) patient drug information (UpToDate)Darolutamide (Nubeqa) patient drug information (UpToDate)
==History of changes in FDA indication==
*2019-07-30: Initial approval for non-metastatic castration-resistant prostate cancer. (Based on ARAMIS)
*2022-08-05: Approved in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). (Based on ARASENS)
==History of changes in EMA indication==
*2020-03-27: Initial authorization as Nubeqa. Nubeqa is indicated for the treatment of adult men with non metastatic castration resistant prostate cancer (nmCRPC) who are at risk of developing metastatic disease. (Based on ARAMIS)
*2023-03-20: Additional indication for metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy. (Based on ARASENS)
==History of changes in Health Canada indication==
*2020-02-20: Notice of compliance for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC).
*2022-09-29: New indication (details unknown)
==History of changes in PMDA indications==
*2020-01-23: Newly indicated for the treatment of non-metastatic, castration-resistant prostate cancer.
==Also known as==
*Code name: BAY-1841788, ODM-201
*Brand name: Nubeqa
==References==
Category:Drugs
Category:Oral medications
Category:Second-generation nonsteroidal antiandrogens
Category:Prostate cancer medications
Category:FDA approved in 2019
Category:EMA approved in 2020
Category:Health Canada approved in 2020
Category:PMDA approved in 2020
Dartmouth-Hitchcock Medical Center Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The mission of the Hematology & Medical Oncology Fellowship Program at Johns Hopkins is to train, inspire, and mentor outstanding leaders in Hematology and Oncology. Our program offers dual or single certification in Hematology or Oncology. Although we are a combined fellowship program, we offer independent tracks in either Hematology or Medical Oncology that provide a unique 12 month training curriculum that is tailored to each specialty."
==Basic information==
Name: Dartmouth-Hitchcock Hematology Oncology Fellowship
Fellowship program website: https://gme.dartmouth-hitchcock.org/hemonc.html
ACGME ID: 1553221038
===Leadership===
*Program Director: Mary Chamberlin, MD
===Fellowship Coordinator===
Rebecca Johnson 
Phone: 603-650-5516
Email: Rebecca.J.Johnson@hitchcock.org
==Application process and requirements==
https://gme.dartmouth-hitchcock.org/hemonc/how_to_apply.html
===Process===
*Applications accepted starting on: July 15th
*Application deadline:
*Applications submitted through ERAS
===Requirements===
*ERAS standard application
*A personal statement
*Medical school dean's letter
*Medical school transcript
*Three letters of recommendation
*Curriculum Vitae
*Valid Standard ECFMG Certificate (if applicable)
*Proof you passed USMLE or COMLEX Steps 1 and 2
==Statistics==
*Number of fellowship positions available per year: 3
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
During the fellowship, 18 months are spent working on designated clinical programs and 18 months are unrestricted so each fellow can pursue personal clinical and research career directions.
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*Dartmouth-Hitchcock Norton Cancer Center 
*White River Junction VA Medical Center, Vermont 
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Datopotamab deruxtecan (Datroway)

==Mechanism of action==
From the NCI Drug Dictionary: An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the datopotamab deruxtecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits tumor cell proliferation of TROP2-expressing tumor cells.
==Diseases for which it is established==
*Breast cancer
==Diseases for which it is used==
*Non-small cell lung cancer
==History of changes in FDA indication==
*2025-01-17: Approved for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC1+ or IHC2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. (Based on TROPION-Breast01)
==Also known as==
*Code name: DS-1062
*Generic name: Dato-DXd
*Brand name: Datroway
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-TROP2 antibody-drug conjugates
Category:Topoisomerase I inhibitors
Category:Breast cancer medications
Category:Non-small cell lung cancer medications
Category:FDA approved in 2025
Daunorubicin (Cerubidine)

==General information==
Class/mechanism: Anthracycline, binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.Daunorubicin (Cerubidine) package insert Daunorubicin (Cerubidine) package insert (locally hosted backup)
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*B-cell acute lymphoblastic leukemia
*Acute myeloid leukemia
*Acute promyelocytic leukemia
*T-cell acute lymphoblastic leukemia
==Toxicity information==
*Per Feijen et al. 2015 Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. J Clin Oncol. 2015 Nov 10;33(32):3774-80. Epub 2015 Aug 24. link to original article link to PMC article EuroPMC
, daunorubicin appears to be significantly less cardiotoxic than doxorubicin in survivors of childhood cancer.
==Patient drug information==
*Daunorubicin (Cerubidine) patient drug information (Chemocare)Daunorubicin (Cerubidine) patient drug information (Chemocare)
*Daunorubicin (Cerubidine) patient drug information (UpToDate)Daunorubicin (Cerubidine) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1979-12-19: Initial FDA approval
*Uncertain date: Approved in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults. (Based on Yates et al. 1973, possibly others)
*Uncertain date: Approved for remission induction in acute lymphocytic leukemia of children and adults. (Based on ALGB 6801 & CALGB 7612)
==History of changes in EMA indication==
*1966-06-08: EURD
==Patient Information==
*Daunorubicin (Cerubidine) package insert
==Also known as==
*Generic name: daunomycin
*Brand names: Cerubidin, Cerubidine, D-Blastin, Daunoblastin, Daunoblastina, Daunocin, Daunomicina, Daunorubicine, Daurocina, Maxidauno, Ondena, Rubidomycin, Rubilem, Rubomycin, Runabicon
==References==
Category:Drugs
Category:Intravenous medications
Category:Vesicant
Category:Anthracyclines
Category:Topoisomerase II inhibitors
Category:B-cell acute lymphoblastic leukemia medications
Category:Acute myeloid leukemia medications
Category:Acute promyelocytic leukemia medications
Category:T-cell acute lymphoblastic leukemia medications
Category:FDA approved in 1979
Category:EMA approved in 1966
Category:WHO Essential Cancer Medicine
Daunorubicin liposomal (DaunoXome)

==General information==
Class/mechanism: Anthracycline enclosed in a liposomal preparation, which protects it from chemical and enzymatic degradation, reduces protein binding, and decreases uptake by normal (non-reticuloendothelial system) tissues. Liposomal preparation may increase accumulation in tumors. Daunorubicin binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.Daunorubicin liposomal (DaunoXome) package insert Daunorubicin liposomal (DaunoXome) package insert (locally hosted backup)DaunoXome manufacturer's website
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it was used==
*Acute myeloid leukemia
*Kaposi sarcoma
==Patient drug information==
*Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)Daunorubicin liposomal (DaunoXome) patient drug information (Chemocare)
*Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)Daunorubicin liposomal (DaunoXome) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1996-04-08: Initial FDA approval as a first-line cytotoxic therapy for the treatment of advanced, HIV-associated Kaposi's sarcoma (KS). (Based on Gill et al. 1996)
==Also known as==
*Generic name: daunorubicin citrate liposome injection
*Brand name: DaunoXome
==References==
Category:Drugs
Category:Intravenous medications
Category:Irritant
Category:Liposomal chemotherapy
Category:Anthracyclines
Category:Topoisomerase II inhibitors
Category:Acute myeloid leukemia medications (historic)
Category:Kaposi sarcoma medications (historic) 
Category:FDA approved in 1996
Category:Discontinued drugs
Decitabine (Dacogen)

==General information==
Class/mechanism: Pyrimidine/cytosine analog, DNA hypomethylating agent. Incorporates into DNA and inhibits DNA methyltransferase, causing DNA hypomethylation, which results in cellular differentiation or apoptosis.Decitabine (Dacogen) package insert Decitabine (Dacogen) package insert (locally hosted backup)
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Acute myeloid leukemia
*Chronic myelomonocytic leukemia
*Myelodysplastic syndrome
==History of changes in FDA indication==
* 2006-05-02: Initial approval for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. (Based on D-0007)
==History of changes in EMA indication==
*2012-09-20: Initial authorization
*Uncertain date: Indicated for treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.
==Patient drug information==
*Decitabine (Dacogen) patient drug information (Chemocare)Decitabine (Dacogen) patient drug information (Chemocare)
*Patient counseling information can be found in the Decitabine (Dacogen) package insert
*Decitabine (Dacogen) patient drug information (UpToDate)Decitabine (Dacogen) patient drug information (UpToDate)
==Also known as==
*Generic name: 5-aza-2'-deoxycytidine
*Brand names: Dacogen, Decima, Decita, Decitafect, Decitas, Decitamyl, Decitex, Deczuba, Natdecita, Mylodec
==References==
Category:Drugs
Category:Intravenous medications
Category:DNA methyltransferase inhibitors
Category:Pyrimidine analogs
Category:Acute myeloid leukemia medications
Category:Chronic myelomonocytic leukemia medications
Category:Myelodysplastic syndrome medications
Category:FDA approved in 2006
Category:EMA approved in 2012
Decitabine and cedazuridine (Inqovi)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available combination agent containing the cytidine deaminase (CDA) inhibitor E7727 and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of decitabine and cedazuridine, the CDA inhibitor E7727 binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increasing its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth. 
==Diseases for which it is used==
*Chronic myelomonocytic leukemia
*Myelodysplastic syndrome
==History of changes in FDA indication==
*2020-07-07: Initial approval for adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. (Based on ASTX727-01-B and ASCERTAIN)
==History of changes in EMA indication==
*2023-09-19: Initial marketing authorization as Inaqovi. Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
== Patient Drug Information==
*Decitaine and cedazuridine (Inqovi) Package InsertDecitaine and cedazuridine (Inqovi) Package Insert
==Also known as==
*Code name: ASTX-727
*Brand name: Inaqovi, Inqovi
==References==
Category:Drugs
Category:Oral medications
Category:DNA methyltransferase inhibitors
Category:Pyrimidine analogs
Category:Chronic myelomonocytic leukemia medications
Category:Myelodysplastic syndrome medications
Category:FDA approved in 2020
Category:EMA approved in 2023
Deep veins and superficial veins in the arms and legs

==Lower extremity deep veins==
Deep veins in the legs/lower extremities include: 
===Proximal veins===
External iliac, internal iliac, common iliac, pelvic (gonadal, broad ligament), common femoral, superficial femoral, deep femoral (profunda), and popliteal veins. Also consider inferior vena cava.
===Distal veins===
Anterior tibial, posterior tibial, peroneal, gastrocnemius, and soleus veins. 
==Lower extremity superficial veins==
Superficial veins in the legs/lower extremities include: greater saphenous and lesser saphenous veins.
==Upper extremity deep veins==
Deep veins in the arms/upper extremities include: radial, ulnar, brachial, axillary, and subclavian veins.
==Upper extremity superficial veins==
Superficial veins in the arms/upper extremities include: Digital, metacarpal, cephalic, basilic, and median veins.
Category:Hematology reference pages
Deferasirox (Exjade)

==General information==
Class/mechanism: Iron chelating agent; selective for the ferric form of iron: iron(III), Fe3+.Deferasirox (Exjade) package insert Deferasirox (Exjade) package insert (locally hosted backup)Exjade manufacturer's website
Route: PO (powder); the PO tablet form of this medication is Deferasirox (Jadenu)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Iron overload, secondary hemochromatosis 
==Patient drug information==
*Brief patient counseling information can be found on Deferasirox (Exjade) package insert pages 21-22
*Deferasirox (Exjade) patient drug information (UpToDate)Deferasirox (Exjade) patient drug information (UpToDate)
==Also known as==
*Brand name: Exjade
==References==
Category:Drugs
Category:Oral medications
Category:Hematology medications
Category:Chelators
Category:FDA approved in 2005
Category:Health Canada approved in 2006
Deferasirox (Jadenu)

==General information==
Class/mechanism: Iron chelating agent; selective for the ferric form of iron: iron(III), Fe3+.Deferasirox (Jadenu) package insert Deferasirox (Jadenu) package insert (locally hosted backup)Jadenu manufacturer's website
Route: PO (tablet); the PO powder form of this medication is Deferasirox (Exjade)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Iron overload, secondary hemochromatosis 
==Patient drug information==
*Patient counseling information can be found in the Deferasirox (Jadenu) package insert
*Deferasirox (Exjade) patient drug information (UpToDate)Deferasirox (Exjade) patient drug information (UpToDate)
==History of changes in FDA indication==
*2015-03-30: Accelerated FDA approval for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.
*2015-03-30: Accelerated FDA approval for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L.
==Also known as==
*Brand name: Jadenu
==References==
Category:Drugs
Category:Oral medications
Category:Hematology medications
Category:Chelators
Category:FDA approved in 2015
Deferiprone (Ferriprox)

==General information==
Class/mechanism: Iron chelating agent; binds with ferric ions and forms neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has higher binding affinity for iron than other metals such as copper, aluminum, and zinc.Deferiprone (Ferriprox) package insert Deferiprone (Ferriprox) package insert (locally hosted backup)Ferriprox manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Patient drug information==
*Deferiprone (Ferriprox) package insert pages 9-12
*Deferiprone (Ferriprox) patient drug information (UpToDate)Deferiprone (Ferriprox) patient drug information (UpToDate)
==Also known as==
*Brand name: Ferriprox
==References==
Category:Drugs
Category:Oral medications
Category:Hematology medications
Category:Chelators
Category:FDA approved in 2011